Samaritan Pharmaceuticals, Inc. Announces Issuance Of Updated Research Report By Taglich Brothers

LAS VEGAS--(BUSINESS WIRE)--Dec. 20, 2005--Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today that Taglich Brothers issued its updated research report. The updated rating lists Samaritan as “neutral” and concludes, “At current prices, the shares of the Company may provide high risk tolerant, bio-technology investors, with a compelling investment opportunity; relative to risk and the success, of any of its development stage product candidates, with significant market potential. Since early 2005, the Company has announced a number of strategic and forward-looking developments. We are very encouraged by these developments; nevertheless, we are maintaining coverage of Samaritan Pharmaceuticals, Inc. (AMEX:LIV) with a Neutral rating, pending further clinical and business developments.”